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A B S T R A C T
Background
Reduction of lung inflammation is one of the goals of cystic fibrosis therapy. Inhaled corticosteroids are often used to treat children
and adults with cystic fibrosis. The rationale for this is their potential to reduce lung damage arising from inflammation, as well as
their effect on symptomatic wheezing. It is important to establish the current level of evidence for the risks and benefits of inhaled
corticosteroids, especially in the light of their known adverse effects on growth. This is an update of a previously published review.
Objectives
To assess the effectiveness of taking regular inhaled corticosteroids, compared to not taking them, in children and adults with cystic
fibrosis.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register, comprising references identified from compre-
hensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We requested
information from pharmaceutical companies manufacturing inhaled corticosteroids and authors of identified trials.
Date of most recent search of the Group’s Trials Register: 15 August 2016.
Selection criteria
Randomised or quasi-randomised trials, published and unpublished, comparing inhaled corticosteroids to placebo or standard treatment
in individuals with cystic fibrosis.
Data collection and analysis
Two independent authors assessed methodological quality and risk of bias in trials using established criteria and extracted data using
standard pro formas.
Main results
The searches identified 34 citations, of which 26 (representing 13 trials) were eligible for inclusion. These 13 trials reported the use of
inhaled corticosteroids in 506 people with cystic fibrosis aged between six and 55 years. One was a withdrawal trial in individuals who
were already taking inhaled corticosteroids. Methodological quality and risk of bias were difficult to assess from published information.
Many of the risk of bias judgements were unclear due to a lack of available information. Only two trials specified how participants
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were randomised and less than half of the included trials gave details on how allocation was concealed. Trials were generally judged to
have a low risk of bias from blinding, except for two which were open label or did not use a placebo. There were some concerns that a
number of trials had not been published in peer-reviewed journals, but the risk of bias from this was unclear. Inclusion criteria varied
between trials, as did type and duration of treatment and timing of outcome assessments. Objective measures of airway function were
reported in most trials but were often incomplete. Significant benefit has not been conclusively demonstrated. Four trials systematically
documented adverse effects and growth was significantly affected in one study using high doses.
Authors’ conclusions
Evidence from these trials is insufficient to establish whether inhaled corticosteroids are beneficial in cystic fibrosis, but withdrawal in
those already taking them has been shown to be safe. There is some evidence they may cause harm in terms of growth. It has not been
established whether long-term use is beneficial in reducing lung inflammation, which should improve survival, but it is unlikely this
will be proven conclusively in a randomised controlled trial.
P L A I N L A N G U A G E S U M M A R Y
Inhaled corticosteroids for cystic fibrosis
Review question
We reviewed the evidence about the effect of inhaled corticosteroids in people with cystic fibrosis.
Background
Repeated chest infections in people with cystic fibrosis cause inflammation and damage to the lungs which, in the long term, is the
most common reason for death in people with cystic fibrosis. Inhaled corticosteroids are often used to treat inflammation, but may
cause some side effects. Some of these side effects are less serious, for example oral thrush, but others are more serious, such as reduced
growth rate in childhood. This is an update of an earlier review.
Search date
The last search for evidence was on 15 August 2016.
Study characteristics
In this updated review, 13 trials reported the use of inhaled corticosteroids in 506 people with cystic fibrosis aged between 6 and
55 years. Three trials were in children only, four in adults only and four were mixed ages; two trials did not describe the ages of the
volunteers. The lung function and severity of disease of the volunteers varied across trials and only two trials gave information about
their genetic mutations. All trials took place in Europe. In 10 of the trials, all volunteers were in the same group up to the end of the
trial (either a treatment group or a group receiving no treatment or a placebo (treatment that appeared the same as the steroids, but did
not have any active medicine in it)), but in three trials they swapped groups halfway through the trial. In most of the trials volunteers
started taking steroids or placebo at the start of the trial, but one trial was a withdrawal trial, where all volunteers were already taking
steroids and half of them carried on and the rest took a placebo, in effect stopping the treatment. The trials lasted between three weeks
and two years.
Key results
The clinical trials have not been able to prove that inhaled corticosteroids reduce inflammation in the lungs of people with cystic
fibrosis. One trial has shown that these drugs can slow down children’s growth when used in high doses. Furthermore it has been shown
that under close supervision of the cystic fibrosis team, it may be safe for people who have been taking inhaled corticosteroids for some
time to stop doing so.
Quality of the evidence
A lack of information meant we were often not able to judge if the way the trials were designed or run could have affected our confidence
in the results. Only two trials gave details of how they made sure volunteers had equal chances of being in the treatment or placebo
groups and only five supplied information on how they made sure the people recruiting volunteers didn’t know which groups they
would be going into. In most cases, we didn’t think that once the trials started the volunteers or their doctors knew whether they were
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getting steroids or placebo. However, we did have some concerns that five of the trials had not been published in journals, that would
send the reports to experts to check for accuracy and we were not sure how this might affect our confidence in the results.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a chronic disorder, of autosomal recessive in-
heritance, which principally affects the respiratory tract, pancreas,
gastro-intestinal tract and liver. In the respiratory tract, abnormal-
ities result in mucus plugging of the airways and susceptibility
to respiratory tract infection. This leads to neutrophil-dominated
airway inflammation with consequent lung damage (bronchiecta-
sis), and eventually respiratory failure and death. Inflammation is
also important in the development of the bronchial hyperreactiv-
ity (BHR) and airway instability that may be associated with CF.
Up to half of people with CF have measurable BHR, which seems
unrelated to atopic status (Burdon 1980; Mitchell 1978; Tobin
1980). Although prognosis and survival continue to improve, it
is the lung damage which is the single most important factor re-
sponsible for premature death. Lung damage also has implications
for quality of life, and slowing of the rate of progression of lung
disease is an important goal in the management of CF. The search
for a suitable anti-inflammatory strategy has gone on for over two
decades, but unfortunately there is still no ideal agent available
(Balfour-Lynn 2007). Lung inflammation may commence very
early in life (Khan1995), andmay be present even in those without
clinical manifestations of lung disease (Armstrong 1995) or posi-
tive bacterial culture (Balough 1995; Konstan 1994). Although a
normal inflammatory response is beneficial to host defence mech-
anisms, the exaggerated response seen in CF contributes to the
morbidity and ultimately the mortality associated with the disease
(Hilliard 2005).
Description of the intervention
Corticosteroids (glucocorticoids) are potent non-specific anti-in-
flammatory agents which have been widely used in a variety of in-
flammatory disorders. They can be administered topically or sys-
temically, but this review is concerned only with corticosteroids
given by the inhaled route.
How the intervention might work
In asthma, inhaled corticosteroids (ICS) reduce BHR and air-
way inflammation (Barnes 1992; Booth 1995; Djukanovic 1992;
van Grunsven 1999) and lead to modest improvements in airway
function (Calpin 1997). Although beneficial effects on pulmonary
function, but not BHR, have been reported in chronic obstruc-
tive pulmonary disease (COPD) (Renkema 1996; Weir 1993),
there is proven benefit only in certain aspects of COPD manage-
ment (NICE 2004). Furthermore, a COPD biopsy study showed
that three months of inhaled fluticasone did not reduce the neu-
trophilic inflammation, despite improvement in symptoms and
exacerbation rate (Hattotuwa 2002).The rationale for their use
in CF lies in observations that inflammation occurs early in the
course of CF and may contribute to lung damage. The Cochrane
Review of evidence for the effectiveness of oral corticosteroids in
CF concluded that treatment with a prednisolone equivalent dose
of 2 mg/kg on alternate days appeared to slow the progression of
lung disease but was associated with a high risk of important side
effects (Cheng 1999).
Corticosteroids are associated with a wide range of potential ad-
verse effects, all of which tend to be more severe with oral or other
systemic preparations (ABPI 1999). Oral administration over pro-
longed periods may lead to a Cushingoid appearance with redistri-
bution of fat to the central areas of the body, obesity, muscle wast-
ing, acne, bruising, thinning of the skin and skin striae. High doses
can also precipitate or exacerbate impaired glucose metabolism.
Prolonged use is associated with reduced bone mineral density
and posterior subcapsular cataracts. In children, one of the most
important side effects is growth suppression. There are also con-
cerns that substantial inhibition of inflammation could impair in-
nate immunity andmake the patient more susceptible to infection
(Koehler 2004).
Inhaled preparations of corticosteroids have been developed to
maximise effective treatment of lung inflammation and reduce the
frequency of harmful effects, but these have not been completely
eliminated (Russell 2004). Systemic adverse effects occur with all
ICS, although to a lesser degree than seen with oral preparations
(Lipworth 1999). These appear to be related to both dose and
duration of treatment. In one meta-analysis, an increased risk of
adrenal suppression and bone thinning was found at daily doses
above 1.5 mg (budesonide equivalent) per day (which equates to
above 0.75 mg per day for fluticasone) (Lipworth 1999). Over the
last decade there has been increasing concern about the potential
effects of ICS on adrenal function, with several case series report-
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ing symptomatic adrenal suppression including hypoglycaemia,
coma and even death in asthmatic adults and children taking high
(and less often standard) dose ICS (Drake 2002; Macdessi 2003;
Patel 2001; Taylor 1999; Todd 1996; Todd 2002). More recently,
there has been a population-based case controlled study suggesting
an association of high doses for long duration may be associated
with cataracts in those over 40 years old (Smeeth 2003). Other
less severe adverse effects include hoarseness of voice and oral can-
didiasis.
Why it is important to do this review
In 1994, in the UK, 34% of adults with CF surveyed reported
that they took inhaled steroids (Walters 1995) and this had risen
to 51% in a subsequent survey conducted in 2000 (Walters 2001).
National databases showed there to have been an increase in pre-
scribing and use both in Europe and the USA. In 1994 and 1995
(snapshot data), databases of annual review returns recorded the
ICS use as 36% in the UK (Koch 1997), and 26% in North Amer-
ica (1995 snapshot data) (Konstan 1999). Clinicians at CF centres
treating children reported prescribing them to a median of 44%
of children (Balfour-Lynn 1999). Data from 2001 entries showed
that in the UK (CF Trust Database) 52% children and 55% adults
were prescribed ICS, whilst in the USA they were given to 41%
children and 48% adults (Epidemiologic Study of CF). Whilst
more recent data from UK CF Trust Registry shows that in 2007,
21% children under 16 years and 23% adults were prescribed reg-
ular ICS; and North American data from the CFF registry showed
that in 2005, 46% patients received ICS (Balfour-Lynn 2008).
The use of ICS may be justified as a form of symptomatic
prophylaxis for those with recurrent wheezing or CF asthma
(Balfour-Lynn 2002), but they are also prescribed by many clin-
icians purely for their perceived benefit as an anti-inflammatory
agent. It is therefore important to establish whether this practice is
beneficial overall for patients with CF or whether their potential
for harm overrides any benefit.
This version of the review is an update of previously published
versions (Balfour-Lynn 2000; Balfour-Lynn 2009; Balfour-Lynn
2012; Balfour-Lynn 2014).
O B J E C T I V E S
The objective of this review was to assess the effectiveness of reg-
ular use of ICS when compared to not receiving ICS, in the man-
agement of people with CF. We assessed whether ICS:
1. improve lung function (including tests of lung function,
bronchial hyperreactivity, exercise tolerance);
2. reduce the need for hospital admission or antibiotic
treatment for respiratory exacerbations;
3. improve the well-being of people with CF (in relation to
nutritional status and quality of life);
4. improve survival;
5. are associated with harmful effects.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials and quasi-randomised controlled tri-
als (using allocation methods such as alternate allocation to treat-
ment and control group) were included.
Types of participants
People with CF who had been diagnosed by clinical criteria and
sweat or genetic testing, or both, regardless of age or clinical sever-
ity.
Types of interventions
Any ICS administered using any inhalation device (including me-
tered dose inhalers, dry powder inhalers, spacer devices and nebu-
lisers) for a period of not less than two weeks, compared to either
placebo or standard treatment.
Types of outcome measures
Primary outcomes
1. Objective measures of lung function
i) absolute change and change in % predicted of forced
expiratory volume in one second (FEV1)
ii) absolute change and change in % predicted of the
forced vital capacity (FVC)
Secondary outcomes
1. Changes in bronchial hyperreactivity as measured by
challenge with a bronchoconstricting agent such as histamine,
methacholine or cold air
2. Objective or subjective improvement in exercise tolerance
3. Number of days in hospital for respiratory exacerbations
4. Number of days on intravenous antibiotics for respiratory
exacerbations
5. Change in nutritional indices
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i) change in height centile
ii) change in weight centile
iii) change in body mass index or per cent predicted
weight for height
iv) changes in growth velocity (change in cm per
treatment interval)
v) other
6. Quality of life
7. Occurrence of any adverse effects
i) local effects (e.g. oral candida infections (diagnosed
clinically or microbiologically), hoarseness)
ii) systemic effects (e.g. skin changes, diabetes mellitus,
osteoporosis, Cushingoid appearance, cataract, mild or severe
opportunistic infection, adrenal insufficiency (post hoc addition))
8. Survival (assessed at 6 months, 12 months and annually
thereafter)
Search methods for identification of studies
Electronic searches
Relevant studies were identified from the Group’s Cystic Fibrosis
Trials Register using the terms: anti-inflammatory AND steroid
AND (inhaled or unknown).
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of The Cochrane Library),
weekly searches ofMEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major CF conferences:
the International Cystic Fibrosis Conference; the European Cystic
Fibrosis Conference and theNorth American Cystic Fibrosis Con-
ference. For full details of all searching activities for the register,
please see the relevant sections of the Cystic Fibrosis and Genetic
Disorders Group Module.
Date of the most recent search of the Group’s Trials Register: 15
August 2016.
Searching other resources
The reference lists of all trials identified were searched. Two phar-
maceutical companies manufacturing ICS preparations were con-
tacted to identify unpublished trials. No trials were identified by
one and we have not yet received a reply from the other. For a
previous update, we wrote to lead authors of nine eligible trials,
published only as abstracts or as full reports but with incomplete
information for assessment of methodological quality or for re-
porting of outcomes. Replies were received from five and any in-
formation provided was incorporated.
Data collection and analysis
Selection of studies
For the update two authors (KW, IBL) independently selected
trials to be included in the review. There was no disagreement
between the authors as to which trials should be included.
Data extraction and management
To ensure consistency, each author independently extracted data
using a standard data extraction form. The outcome measures
listed above were assessed in the short term (between 2 and 12
weeks), the medium term (between 3 and 12 months) and long
term (over 12 months).
TheWISE trial is a withdrawal study and all participants had been
on steroids for a number of years before these were withdrawn. The
other studies present data from the start of treatment with steroids.
The review authors decided that the data from the withdrawal
study should be presented on a different graph to the data from
the other studies since the populations in the placebo arms of the
studies are heterogeneous and that there may possibly be carry
over effect which will tend to reduce the difference.
Assessment of risk of bias in included studies
We used the criteria for assessing risk of bias as provided in
the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2008). We asked if the six domains listed below were
considered to be adequate.There were three possible responses,
’yes’, ’no’ or ’unclear’. ‘Yes’ indicated a low risk of bias, and ‘no’
indicated high risk of bias. If insufficient detail was reported the
judgement was ‘unclear’ risk of bias. We assessed the new studies
included in the updated review and we reassessed the studies al-
ready included in the old review using the new criteria.
Sequence generation
’Yes’, if the allocation sequence was generated using techniques
such as a random number table; a computer random number gen-
erator; coin tossing; shuffling cards or envelopes; throwing dice.
’No’, if the allocation sequence was generated using techniques
such as odd or even date of birth; date (or day) of admission;
hospital or clinic record number.
’Unclear’, if there was insufficient information about the sequence
generation process to permit judgement of ‘Yes’ or ‘No’.
Allocation concealment
’Yes’, if the allocation concealment used methods such as central
allocation (including telephone, web-based and pharmacy-con-
trolled randomization); sequentially numbered drug containers of
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identical appearance; sequentially numbered, opaque, sealed en-
velopes.
’No’, if the participants or investigators enrolling participants
could possibly foresee assignments and thus introduce selection
bias, such as allocation based on; using an open random allocation
schedule (e.g. a list of random numbers); assignment envelopes
used without appropriate safeguards (e.g. if envelopes were un-
sealed or non-opaque or not sequentially numbered); alternation
or rotation; date of birth; case record number.
’Unclear’, if there was insufficient information to permit judge-
ment of ‘Yes’ or ‘No’. This was usually the case if the method of
concealment was not described or not described in sufficient de-
tail to allow a definite judgement for example if the use of assign-
ment envelopes was described, but it remained unclear whether
envelopes were sequentially numbered, opaque and sealed.
Blinding
’Yes’, if there was no blinding, but the review authors judged that
the outcome and the outcome measurement was not likely to be
influenced by lack of blinding; blinding of participants and key
study personnel was ensured, and unlikely that the blinding could
have been broken; either participants or some key study personnel
were not blinded, but outcome assessment was blinded and the
non-blinding of others unlikely to introduce bias.
’No’, if there was no blinding or incomplete blinding, and the out-
come or outcome measurement was likely to be influenced by lack
of blinding; blinding of key study participants and personnel was
attempted, but likely that the blinding could have been broken;
either participants or some key study personnel were not blinded,
and the non-blinding of others was likely to introduce bias.
’Unclear’, if there was insufficient information to permit judge-
ment of ‘Yes’ or ‘No’ or the study did not address this outcome.
Incomplete data assessment
’Yes’, if there were no missing outcome data; reasons for missing
outcome data were unlikely to be related to true outcome; miss-
ing outcome data was balanced in numbers across intervention
groups, with similar reasons for missing data across groups; for
dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk was not enough to have a clin-
ically relevant impact on the intervention effect estimate; for con-
tinuous outcome data, plausible effect size (difference in means or
standardized difference in means) among missing outcomes was
not enough to have a clinically relevant impact on observed effect
size; missing data were imputed using appropriate methods.
’No’, if reason for missing outcome data were likely to be related
to true outcome, with either imbalance in numbers or reasons
for missing data across intervention groups; for dichotomous out-
come data, the proportion of missing outcomes compared with
observed event risk was enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes was enough to induce clinically
relevant bias in observed effect size; ‘As-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomization; potentially inappropriate application of
simple imputation.
’Unclear’, if there was insufficient reporting of attrition or exclu-
sions to permit judgement of ‘Yes’ or ‘No’ (e.g. number random-
ized were not stated, no reasons for missing data were provided);
the study did not address this outcome.
Selective outcome reporting
’Yes’, if the study protocol was available and all of the study’s pre-
specified (primary and secondary) outcomes that were of interest
in the review were reported in the pre-specified way; the study
protocol was not available but it was clear that the published re-
ports included all expected outcomes, including those that were
pre-specified.
’No’, if not all of the study’s pre-specified primary outcomes were
reported; one or more primary outcomes was reported using mea-
surements, analysis methods or subsets of the data (e.g. sub scales)
that were not pre-specified; one or more reported primary out-
comes were not pre-specified (unless clear justification for their
reporting was provided, such as an unexpected adverse effect); one
or more outcomes of interest in the review were reported incom-
pletely so that they could not be entered in a meta-analysis; the
study report failed to include results for a key outcome that would
be expected to have been reported for such a study.
’Unclear’, if there was insufficient information to permit judge-
ment of ‘Yes’ or ‘No’.
Other sources of bias
’Yes’, if the study appeared to be free of other sources of bias.
’No’, if there was at least one important risk of bias. For example,
the study had a potential source of bias related to the specific
study design used; or stopped early due to some data-dependent
process (including a formal-stopping rule); or had extreme baseline
imbalance; or has been claimed to have been fraudulent; or had
some other problem.
’Unclear’, if there was either: insufficient information to assess
whether an important risk of bias existed; or insufficient rationale
or evidence that an identified problem would introduce bias.
Measures of treatment effect
The statistical analysis proposed, included calculation of a pooled
estimate of treatment effect for each dichotomous outcome across
all studies (odds of outcome in participants allocated to receive
treatment compared with odds of outcome in participants allo-
cated to control group); and calculation of a pooled estimate of
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treatment effect for each continuous outcome across all studies in
the form of a mean difference (MD). For continuous variables,
the authors recorded mean absolute change from baseline for each
group, or mean post-treatment values and standard deviation for
each group.
Unit of analysis issues
Elbourne discusses methods for meta-analysing cross-over trials
(Elbourne 2002). The methods discussed rely on the data that
are reported within the primary paper. The method that has been
adopted within this review uses data from the first period only,
ignoring the second period data. If results of the first period only
were not available, the results of the trial were described in the
text.
Dealing with missing data
In order to allow an intention-to-treat analysis, the authors sought
data on the number of participants with each outcome event listed
above, by allocated treatment group, irrespective of whether the
participant complied with treatment or was later excluded from
treatment or follow up.
The authors also contacted the study investigators for clarification
of information in their publications or additional data where nec-
essary.
Assessment of heterogeneity
If indicated, the authors examined heterogeneity between trial
results using a standard chi-squared test. The authors also assessed
the degree of heterogeneity between trials using the I2 statistic
(Higgins 2003). This measure describes the percentage of total
variation across studies that are due to heterogeneity rather than
by chance; the values of I2 lie between 0% and 100%, and can be
simply categorized so that heterogeneity is low when I2 has a value
of 25%, moderate if I2 has a value of 50%, and high when I2 has
a value of 75% (Higgins 2003).
Assessment of reporting biases
Reports of all the included studies were checked to see that all the
stated outcomes were reported and the results are presented in the
’Risk of bias table’ in Characteristics of included studies
Data synthesis
The authors have analysed the data using a fixed-effect model. If,
in future updates of this review, they are able to combine data
and establish a moderate or high degree of heterogeneity between
trials, they will analyse the combined data using a random-effects
model.
Subgroup analysis and investigation of heterogeneity
If there are a sufficient number of trials included in a future update
and heterogeneity is identified, the authors plan to investigate
this by undertaking subgroup analyses comparing age, atopy with
non-atopy, baseline lung function and individuals infected with
Pseudomonas aeruginosa with those not infected with Pseudomonas
aeruginosa. It is unlikely, however, that this will be possible.
Sensitivity analysis
If appropriate, the authors planned to undertake a sensitivity anal-
ysis by allocation method (quasi-randomised versus randomised).
R E S U L T S
Description of studies
Results of the search
The searches identified 34 citations, of which 26 referred to 13
trials meeting the inclusion criteria for this review (Austrian Trial
1995; Belgian Trial 2007; Canadian Trial 1997; CF WISE 2006;
Danish Trial 1983; Danish Trial 1997; Dutch Trial 1995; German
Trial 1999; Irish Trial 1995; Swiss Trial 1996; Turkish Trial 2008;
UK Trial 1996; UK Trial 1997).
Seven citations referred to four trials, all of which were excluded
(Australia Trial 2000; Bessaci 2008; USA Trial 1996; USA Trial
1998). The final citation referred to a trial which is currently listed
in Studies awaiting classification until the methods of the trial can
be clarified with the investigators (Kapustina 2008).
Included studies
Full reports have been published for both Danish trials (Danish
Trial 1983; Danish Trial 1997), the Dutch and Swiss trials (Dutch
Trial 1995; Swiss Trial 1996), two UK trials (CF WISE 2006;
UK Trial 1997), the German trial (German Trial 1999) and the
Belgian trial (Belgian Trial 2007). There are five trials reported
in abstracts or conference proceedings only (Austrian Trial 1995;
Canadian Trial 1997; Irish Trial 1995; Turkish Trial 2008; UK
Trial 1996).
Trial Design
Ten trials were parallel in design (Austrian Trial 1995; Belgian Trial
2007; Canadian Trial 1997; CF WISE 2006; Danish Trial 1983;
Danish Trial 1997; German Trial 1999; Swiss Trial 1996; Turkish
Trial 2008; UK Trial 1996; ) and three were cross-over in design
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(Dutch Trial 1995; Irish Trial 1995; UKTrial 1997). One trial was
a withdrawal trial in which participants who were already taking
inhaled fluticasone were randomised to continue fluticasone or
start placebo (CFWISE 2006). All trials were placebo-controlled,
with the exception of two (German Trial 1999; Swiss Trial 1996).
Eleven trials were based in a single centre (Austrian Trial 1995;
Canadian Trial 1997; Danish Trial 1983; Danish Trial 1997;
Dutch Trial 1995; German Trial 1999; Irish Trial 1995; Swiss
Trial 1996; Turkish Trial 2008; UK Trial 1996; UK Trial 1997)
and two were multicenter (Belgian Trial 2007; CF WISE 2006).
Overall they randomised between 7 and 171 participants per trial;
collectively they randomised 506 participants. Ten trials reported
sex distribution: in these trials, 49.6% (206 out of 415) of partic-
ipants randomised were male.
Participants
Three trials were specifically in children (Canadian Trial 1997;UK
Trial 1997; Belgian Trial 2007), four trials included both children
and adults (CF WISE 2006; Danish Trial 1983; Danish Trial
1997; Swiss Trial 1996) and four enrolled only adults (Dutch Trial
1995; GermanTrial 1999; Irish Trial 1995; UKTrial 1996). In the
remaining two trials it was not explicitly stated whether children
or adults or both were enrolled; although one was conducted in a
paediatric department (Austrian Trial 1995) and the other stated
themean age of participants as 10.5 years old (Turkish Trial 2008).
Participant eligibility was based on clinical diagnosis of CF, usually
with confirmation by sweat test. Two trials reported genotype dis-
tribution (CF WISE 2006; UK Trial 1997). Eligibility according
to severity of pulmonary involvement varied between the trials.
Acute pulmonary exacerbation was an entry criterion in the Aus-
trian trial (Austrian Trial 1995); chronic Pseudomonas aeruginosa
lung infection in both Danish trials (Danish Trial 1983; Danish
Trial 1997); moderate to severe bronchial obstruction (FEV1 less
than 55% predicted) in the Swiss trial (Swiss Trial 1996); ’mild
disease’ (mean FEV1 85% predicted) in the Irish trial (Irish Trial
1995); ’established pulmonary disease’ in the 1996 UK trial (UK
Trial 1996); and ’stable’ disease in the German trial (German Trial
1999). In the Belgian trial participants had mild to moderate lung
disease and FEV1 had to be at least 60% predicted (Belgian Trial
2007). In the withdrawal trial, FEV1 had to be greater than or
equal to 40% predicted and participants had to have been taking
ICS for more than three months (CF WISE 2006). Where ex-
clusion criteria were stated, these generally included recent treat-
ment with oral or ICS and allergic bronchopulmonary aspergillo-
sis. Two trials excluded people with asthma but not those with
atopy (Danish Trial 1997; UK Trial 1997).
Interventions
Beclomethasonewas given for periods of between four and twenty-
two weeks in four trials (Austrian Trial 1995; Danish Trial 1983;
Irish Trial 1995; Swiss Trial 1996); budesonide for six weeks and
six months in two trials (Danish Trial 1997; Dutch Trial 1995);
and fluticasone for periods of between three weeks and two years
in four trials (Belgian Trial 2007; Canadian Trial 1997; German
Trial 1999; UK Trial 1996); in one trial the active treatment was
budesonide, but duration of treatment was not specified (Turkish
Trial 2008).
In four trials, the active treatment was inhaled beclomethasone,
given via metered dose inhaler with or without a spacer device
(Austrian Trial 1995; Danish Trial 1983; Irish Trial 1995; Swiss
Trial 1996). The daily dosage schedule was 1500 mcg except in the
Danish trial, where it was 400 mcg (Danish Trial 1983). Duration
of active treatment assessed ranged from four to twenty-twoweeks.
In two trials, the active treatment was budesonide, total daily dose
1600 mcg given as dry powder for six months (Danish Trial 1997)
or by metered dose inhaler for six weeks (Dutch Trial 1995).
In the remaining trials, the active intervention was fluticasone
propionate given as 1000 mcg daily by metered dose inhaler with
a spacer device for 22 days (German Trial 1999) or for one year
(Belgian Trial 2007; Canadian Trial 1997) or for two years (UK
Trial 1996) or as 800 mcg daily as a dry powder for six weeks (UK
Trial 1997).
In the withdrawal trial there was a two-month period in which
participants either continued to take fluticasone propionate via a
spacer device or were switched to an equivalent dose of fluticasone
propionate if they were already taking budesonide or beclometha-
sone dipropionate (CFWISE 2006). After the two-month period
they were then randomised to continue taking to fluticasone pro-
pionate or start a placebo.
With the exception of the Swiss trial (Swiss Trial 1996), all treat-
ment was given on an outpatient basis.
Outcomes
Lung function measurements were a specified outcome in 11 tri-
als, but were not reported in two (Canadian Trial 1997; Irish
Trial 1995). Following communication with the authors of the
Canadian trial, data on FEV1 have been provided (Canadian Trial
1997). Two cross-over trials reported FEV1 and FVC (Dutch Trial
1995; UK Trial 1997). The Dutch trial reported mean absolute
FEV1 and FVCbutwithout the standard deviations (SDs) for each
treatment period (Dutch Trial 1995). The 1997 UK trial reported
the mean per cent predicted FEV1 and FVC with 95% confi-
dence intervals (CI) for each treatment period (UK Trial 1997).
In further communication with the author of the latter trial, data
(SDs) have been provided for FEV1 and FVC and have been up-
dated in the relevant graphs. In the Swiss trial, FEV1 and FVC
were reported as mean change in per cent predicted but without
SDs (Swiss Trial 1996). In the 1983 Danish trial, the median and
range at baseline and after treatment were reported for these lung
function data (Danish Trial 1983). In the 1996 UK trial, FEV1
and FVC were reported as absolute means and SDs at baseline, 6
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months and 24 months (UK Trial 1996); and in the 1997 Danish
trial, as absolute change from baseline but without SDs at three
and six months (Danish Trial 1997); whereas, in the German trial
they were reported as mean per cent predicted and SD at baseline
and after 21 days treatment (German Trial 1999). The CF-WISE
trial reported mean % predicted FEV1 and FVC at baseline, two,
four and six months and mean % change in % predicted FEV1
and FVC at the same time points. In the de Boeck trial, mean
% predicted FEV1 were reported at baseline, 6 and 12 months
pre- and 20 minutes post-salbutamol (bronchodilator) as a mea-
sure of bronchial lability (Belgian Trial 2007). Mean change in %
predicted FEV1 post-salbutamol and % predicted FVC were also
reported.
Bronchial reactivity was assessed in four trials: by histamine chal-
lenge alone (Dutch Trial 1995); histamine challenge or exercise
test (Danish Trial 1997); or by methacholine challenge (Irish Trial
1995, Turkish Trial 2008). In the Dutch cross-over trial, results
were expressed as mean log PC20 and as geometric mean PC20 at
baseline and after budesonide, but no data were reported for the
placebo treatment period (Dutch Trial 1995). In the 1997 Danish
trial, data were expressed as mean change in histamine dose steps
from baseline within each group, but without SDs, and as mean
difference in mean change in histamine dose steps with 95% CI
between groups (Danish Trial 1997). Data were not reported in
either the Irish or the Turkish trials (Irish Trial 1995; Turkish Trial
2008).
Hospital admissions and antibiotic usage were specified as out-
comes in the Dutch trial, but no data were reported (Dutch Trial
1995). Overall antibiotic usage was reported in the 1996 UK trial,
but not by treatment group (UK Trial 1996). Data regarding pa-
tient days in hospital and patient days on antibiotics were provided
for the previous update by the Canadian investigators (Canadian
Trial 1997). In the CF-WISE withdrawal trial, the primary out-
come reported was the time to first respiratory exacerbation. Sec-
ondary outcomes reported were the number of participants who
had unplanned courses of oral or intravenous antibiotics and the
median number of courses required per participant. The num-
ber of individuals requiring rescue bronchodilator and the median
number of doses per participant were also reported (CF WISE
2006). The deBoeck trial reported themeannumber of respiratory
exacerbations between groups and reported Brasfield chest X-ray
scores (median and quartiles) at baseline, six and twelve months
(Belgian Trial 2007).
Symptoms were specified as outcomes in four trials (Dutch Trial
1995;GermanTrial 1999;UKTrial 1996;UKTrial 1997). The in-
cidence of P. aeruginosa positive respiratory cultures were recorded
in two trials ( Belgian Trial 2007; CF WISE 2006).
Clinical status and nutritional indices were specified as outcomes
in theCanadian trial but have not been reported to date (Canadian
Trial 1997). Change in longitudinal growth (height) was recorded
at baseline then at three monthly intervals during the treatment
duration of one year and then for a further one year after discon-
tinuation (and for up to two years in a subgroup of participants)
in the Belgian trial (Belgian Trial 2007). In the CF-WISE with-
drawal trial, height was measured at the start and end of the trial in
the paediatric participants (CF WISE 2006). The review authors
were provided with these data. The UK trial assessed well-being
and appetite using a visual analogue scale (UK Trial 1997); but
formal measurement of quality of life was not attempted in any
trial.
Number of deaths was reported in one trial (CFWISE 2006); but
no other information on survival was reported in any other trial.
Specific adverse effects were recorded in five trials (Belgian Trial
2007; Canadian Trial 1997; CF WISE 2006; Danish Trial 1997;
UK Trial 1997). In two trials, adverse effects were reported as
not differing significantly or not occurring but no details were
provided (Dutch Trial 1995; UK Trial 1996). In the remaining
trials no comment about adverse effects was made.
Sputum or serum markers of inflammation were measured in six
trials (Austrian Trial 1995; Danish Trial 1983; GermanTrial 1999;
Irish Trial 1995; UK Trial 1997; Turkish Trial 2008),serum IgG
andHba1Cwere recorded at baseline, 6 and 12months in one trial
(Belgian Trial 2007) and oxidative status as measured by plasma
malondialdehyde in one trial (Turkish Trial 2008) - but these are
not specified outcomes for this review.
Adherence to treatment was monitored and reported in the two
trials using fluticasone delivered byDiskhalers (Danish Trial 1997;
UK Trial 1997).
Excluded studies
Four trials (seven citations) were excluded (Australia Trial 2000;
Bessaci 2008; USA Trial 1996; USA Trial 1998). Two citations
referring to one trial from the USA were identified, but this trial
was deemed ineligible, as the outcomes reported were not specified
as outcomes for this review (USA Trial 1998). A further two cita-
tions related to an observational study from the USA which did
not meet the inclusion criteria as treatment had not been allocated
on a random basis (USA Trial 1996). Published details for the
trial referred to in the third citation were insufficient to determine
whether treatments were allocated by random or quasi-random
methods (Australia Trial 2000) and further details could not be
obtained from the authors, therefore this trial was excluded. Two
references identified relate to a trial of seretide (which contains
an inhaled steroid) plus salmeterol which is not a steroid (Bessaci
2008). Since this trial does not consider an ICS alone, it can not
be included.
Risk of bias in included studies
For the 2008 update, in order to establish a risk of bias for the
included trials, two authors (KW, IBL) independently assessed
methodological quality using criteria suggested by Schulz (Schulz
9Inhaled corticosteroids for cystic fibrosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1995). Concealment of allocation and method used to generate
the random sequence were assigned to one of three categories: ade-
quate, unclear or inadequate which related to a low, unclear or high
risk of bias respectively. The reported intention-to-treat analysis
was defined as complete, when less than 15% of participants were
excluded, or incomplete whenmore than 15%were excluded from
the final analysis, where the risk of bias increased as the number of
participants excluded from the final analysis increased. Reporting
of double blinding was recorded as either present or absent; the
absence of blinding was considered to lead to a high risk of bias.
Minor differences between the two authors in determining ade-
quacy of random sequence generation in one trial and conceal-
ment of allocation in two trials were resolved by discussion, as
were differences in assessing the completeness of intention-to-treat
analysis in two trials. Assessments were otherwise concordant. For
a previous update, authors were contacted and asked to clarify
methodological issues, including randomisation method and steps
undertaken to ensure concealment of allocation. Account has been
taken of relevant information received.
Allocation
The method used to generate the random sequence was clearly
mentioned in three trials, which we judged to have a low risk of
bias: the German trial, which used a random number row to de-
termine the intervention for the first participant, and then used
alternation to determine the groups for the remaining participants
(German Trial 1999); the CF WISE trial, which used randomisa-
tion by permuted blocks of four (CF WISE 2006); and the Bel-
gian trial, which used random numbers (Belgian Trial 2007). The
method of randomisation in the other trials is unclear and not
stated in the trial reports. These other trials therefore have an un-
clear risk of bias.
Concealment of allocation was deemed to be adequate in six trials,
which therefore had a low risk of bias: in one trial it was stated that
treatment codes were not broken before clean file was declared by
the data manager (Danish Trial 1997); in the Dutch trial treat-
ment and placebo were given by blinded metered dose inhalers
supplied by pharmaceutical company (Dutch Trial 1995); and in
the CF WISE trial allocation was carried out independently over
the telephone from the Clinical Trials & Evaluation Unit of Royal
Brompton Hospital to the trial centre (CF WISE 2006). Trialists
supplied information from three trials where sealed envelopes were
used, therefore the risk of bias in these trials was low (Canadian
Trial 1997; Irish Trial 1995; UK Trial 1997). Concealment of al-
location was deemed to be inadequate in the German trial which
used a method of alternation allowing the trial investigators to
foresee to which group the next participant would be assigned;
this trial was judged to have a risk of bias (German Trial 1999).
The remaining trials did not discuss allocation concealment and
were judged to have an unclear risk of bias.
Blinding
Nine trials were described as double-blind and judged to have a
low risk of bias (Austrian Trial 1995; Belgian Trial 2007; Canadian
Trial 1997;CFWISE2006;DanishTrial 1983;Danish Trial 1997;
Dutch Trial 1995; Irish Trial 1995; UK Trial 1997). In one trial
there was an unclear risk of bias as blinding was not discussed
(Turkish Trial 2008). In the two remaining trials there was a risk
of bias; one trial was described as open label (German Trial 1999)
and in the other trial there was no placebo arm (Swiss Trial 1996).
Details of the methods used are listed in the ’Risk of bias tables’
in the Characteristics of included studies.
Incomplete outcome data
In three trials an intention-to-treat analysis was based on all par-
ticipants (CF WISE 2006; Danish Trial 1997; Irish Trial 1995):
in two trials less than 15% of participants were excluded (Belgian
Trial 2007; UK Trial 1997); in two trials more than 15% of par-
ticipants were excluded but reasons were given for their exclusion
and the numbers were equal across groups (Danish Trial 1983;
UK Trial 1996). These trials therefore have a low risk of bias. Rea-
sons for exclusion included clinical deterioration, failure to take
treatment or failure to attend for the follow-up assessments. In the
remainder of the trials this could not be judged from the infor-
mation available, and these were judged to have an unclear risk of
bias.
Selective reporting
We examined the published papers and identified the following
instances of selective reporting which could be a potential source
of bias. Hospital admissions and antibiotic usage were specified as
outcomes in the Dutch trial, but no data were reported (Dutch
Trial 1995). Clinical status and nutritional indices were specified
as outcomes in the Canadian trial but have not been reported to
date (Canadian Trial 1997). FVC was recorded, but not reported,
in the 1996UK trial (UKTrial 1996). Although participants in the
1996 UK trial kept a symptom diary card, data were not reported
(UK Trial 1996).
Other potential sources of bias
The Canadian trial was halted prematurely making it difficult to
draw any conclusions (Canadian Trial 1997). A number of trials
have never been published in peer-reviewed journals (Austrian
Trial 1995; Canadian Trial 1997; Irish Trial 1995; Turkish Trial
2008; UK Trial 1996). The Dutch trial was of cross-over design,
but did not describe any washout period; we have judged this trial
to have an unclear risk of bias
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Effects of interventions
We were unable to undertake pooled analyses of any treatment
outcome partly because reports differed in the way data were sum-
marised and partly because some data needed for the analysis, for
example SDs or standard errors (SEs), were not available from
the published reports. As stated above, data from the CF WISE
trial are presented, but results from this trial were not pooled with
other trials because the trial was a withdrawal trial (CF WISE
2006). There were also differences between trials in the outcomes
reported, so that for some variables, only a single trial result could
be reported. The results are presented by outcome in the order in
which they appear in the aims of the review.Within each outcome,
data are discussed separately for parallel and cross-over trials but
sequenced by short-, medium- and long-term outcomes as speci-
fied in the Methods section.
Primary outcome
1. Objective measures of lung function
a. Forced expiratory volume in one second (FEV1)
Four trials reported data for absolute FEV1 (Danish Trial 1997;
Dutch Trial 1995; UK Trial 1996; UK Trial 1997). Analyses of
absolute FEV1 based on all participants randomised were reported
for the 1997 Danish trial, but as no SDs were reported or have
been provided subsequently, these data cannot be included in the
Data and analyses section (Danish Trial 1997). After the first three-
month treatment period in this trial, FEV1 fell by a mean of 32
ml in the budesonide group (n = 30) compared with 187 ml in the
placebo group (n = 25). The between group difference in change
from baseline was reported by the authors as not significant (P =
0.08). When both three-month treatment periods were examined
together, representing six months of treatment, absolute change in
FEV1 after six months of treatment was 2 ml for the budesonide
and -98 ml for the placebo group, reported by the authors as not
statistically significant (P > 0.1) (Danish Trial 1997).
In the Dutch cross-over trial, mean FEV1 was reported as similar
at the end of both six-week treatment periods, being 2.3 L after
budesonide and 2.2 L after placebo. These data were based on 12
of the original 16 participants randomised (Dutch Trial 1995).
Further data (including SDs) are not available from the authors,
so these data cannot be included in the Data and analyses tables.
In the 1996 UK trial, after six months of fluticasone or placebo,
mean absolute FEV1 tended to be higher in the treatment (n = 18)
than in the placebo group (n = 15), but this was not statistically
significant, mean difference (MD) 0.16 L (95% CI -0.27 to 0.59)
(UK Trial 1996). Three participants in the placebo group were
not included in this analysis (less than 15% exclusions). After 24
months of treatment, no significant differences between groups
were observed but this analysis was based on less than half (n = 17)
of the 36 participants originally randomised, MD 0.24 L (95%
CI -0.34 to 0.82). The authors were contacted but were unable to
provide further data for this trial (UK Trial 1996).
In the 1997 UK cross-over trial, mean%predicted FEV1 (SD) was
similar at the end of both six-week treatment periods, being 66%
(16.7) after fluticasone and 67% (23.0) after placebo, with 95%CI
for the difference reported as -8% to 4% (UK Trial 1997). These
data were based on 22 of 23 participants originally randomised.
The data are not entered into the Data and analyses tables as first
period data could not be extracted.
Changes in % predicted FEV1 at different time points were
recorded in three trials (Belgian Trial 2007; CFWISE 2006; Swiss
Trial 1996). In the Belgian trial data were reported after six and 12
months pre- and post-salbutamol bronchodilator (Belgian Trial
2007). No significant difference was found in the percent pre-
dicted FEV1 between those in the treatment (n = 12) and placebo
(n = 15) groups: pre salbutamol at six months, MD 4.00% (95%
CI -7.08% to 15.08%); post salbutamol at six months, MD -
2.00%(95%CI -11.79%to 7.79%); pre salbutamol at 12months,
MD 2.00% (95% CI -12.12% to 16.12%); post salbutamol at
12 months, MD -1.00% (95% CI -12.42% to 10.42%) (Belgian
Trial 2007). In the CF WISE trial no significant difference was
found after six months between those participants who continued
treatment (n = 84) and those who were withdrawn (n = 87), MD
3.00% (95% CI -2.55% to 8.55%) (CF WISE 2006). Addition-
ally, in this trial, no change in lung function was found in the
fluticasone group in those switching from a different ICS (budes-
onide or beclomethasone) to fluticasone (CFWISE 2006). In the
Swiss trial, where treatment was given for 30 days as an inpatient
and assessed at 30 days, there was an improvement in % predicted
FEV1 in those given (n = 25) and not given (n = 24) beclometha-
sone and the between group difference in this improvement was
reported by the authors as not statistically significant (Swiss Trial
1996). From the data reported, the MD at discharge was 3.60%
(95% CI -5.13% to 12.33%) (Swiss Trial 1996).
Following communication with the authors of the Canadian trial,
data have been provided which showed no significant difference
at baseline in FEV1 (Canadian Trial 1997). Illustrations were also
provided which the authors interpreted as showing that lung func-
tion did not alter through the trial in either group over a nine-
month period. However, no actual data were available beyond
baseline (Canadian Trial 1997).
b. Forced vital capacity (FVC)
Five trials measured absolute FVC (Danish Trial 1983; Danish
Trial 1997; Dutch Trial 1995; UK Trial 1996; UK Trial 1997).
In the 1983 Danish trial, median (range) % predicted FVC was
91% (51% to 112%) and 78% (46% to 116%) after 16 weeks
of treatment in the beclomethasone and placebo groups respec-
tively, using data from13 of the originally randomised 24matched
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pairs (Danish Trial 1983). This trial was based on randomisation
within matched pairs, but this was not reflected in the analyses
which compared group means rather than within-pair differences
(Danish Trial 1983). In the 1997 Danish trial, FVC data were
not reported but the authors noted that these followed the same
pattern as FEV1 after three months and six months of treatment
(Danish Trial 1997). In the Dutch cross-over trial, absolute mean
FVC was similar after both six-week treatment periods (3.6 L on
budesonide and 3.3 L on placebo) (Dutch Trial 1995). In the 1996
UK trial, FVC was recorded but not reported (UK Trial 1996).
In the 1997 UK cross-over trial, mean (SD) FVC was 78.4% pre-
dicted (12.6) for the active treatment period and 77.4% (21.9) for
the placebo treatment period (UK Trial 1997). The data are not
entered into the Data and analyses tables as first-period data could
not be extracted.
Three trials recorded change data for FVC (Belgian Trial 2007;
CF WISE 2006; Swiss Trial 1996). In the Swiss trial, between-
group differences in change in % predicted FVC after 30 days of
treatment were reported by the authors as not statistically signifi-
cant, being 9.9% for the beclomethasone group and 7.9% for the
control group (Swiss Trial 1996). From the data reported, we have
calculated the MD at discharge as -0.80% (95% CI -10.02% to
8.42%) (Swiss Trial 1996). In the Belgian trial there was no sig-
nificant difference found in the change in % predicted FVC at six
months, MD -1.00% (95% CI -8.06% to 6.06%) or 12 months,
MD 1.00% (95% CI -10.42% to 12.42%) (Belgian Trial 2007).
No significant difference was found in the % predicted FVC after
six months in the withdrawal trial, where the MD was calculated
to be 0.00% (95% CI -4.95% to 4.95%) (CF WISE 2006).
Secondary outcomes
1. Changes in bronchial hyperreactivity as measured by
challenge with a bronchoconstricting agent such as
histamine, methacholine or cold air
In theDutch trial, analyses based on 12 participants were reported
as showing significant increases in mean log PC20 histamine and
geometric mean PC20 histamine in the budesonide treatment pe-
riod, but no equivalent data or report were given for the placebo
period (Dutch Trial 1995). In the 1997 Danish trial, histamine
PC20 was performed in 41of 55 recruited participants, reported
to increase by significantly more dose steps in those on budesonide
compared with those on placebo,MD in change in histamine dose
steps was reported in the full published paper as 1.13% (95%
CI 0.01% to 2.26%) (P < 0.05) (Danish Trial 1997). Response
to exercise was reported as unchanged. Bronchial hyperreactivity
was measured with metacholine challenge in the Turkish trial and
found to be unchanged between groups (Turkish Trial 2008).
2. Number of days in hospital for respiratory exacerbations
In the Canadian trial, there was no significant difference in the
number of patient days in hospital at the nine-month follow up,
MD -0.10 days (95% CI -12.51 days to 12.31 days) (Canadian
Trial 1997). TheCFWISEwithdrawal trial reported no significant
difference in the time until the first exacerbation between the par-
ticipants who continued treatment and those whowere withdrawn
from fluticasone (CF WISE 2006). No significant difference was
found in the number of respiratory exacerbations between groups
in the Belgian trial (Belgian Trial 2007).
3. Number of days on intravenous antibiotic for respiratory
exacerbations
In the Canadian trial, there was no significant difference in the
number of patient days on antibiotics at the nine-month follow
up, MD -4.40 days (95%CI -50.44 to 41.64) (Canadian Trial
1997).
There was no difference in intravenous (or oral) antibiotic use
between the two groups in the CF WISE trial (CF WISE 2006).
In the 1997UK trial, no significant change in respiratory symptom
scores was reported between the two six-week treatment periods
(UK Trial 1997).
Although participants in the 1996 UK trial kept a symptom diary
card, data were not reported (UKTrial 1996). In the Dutch trial, a
small but significant (P < 0.05) improvement in cough or dyspnoea
after six weeks of treatment was reported by adults randomised to
budesonide (Dutch Trial 1995).
4. Objective or subjective improvement in exercise tolerance
In theDutch trial, comparing the budesonidewith placebo groups,
the mean score was, respectively, 0.38 and 0.54 for dyspnoea at
rest, 0.98 and 0.97 for dyspnoea on exercise, 1.14 and 1.20 for
cough and 2.3 and 2.3 for sputum production (scores were from
zero to three with three being most severe) (Dutch Trial 1995).
5. Change in nutritional indices
In the 1997 UK trial, no significant change in appetite scores was
reported between the two six-week treatment periods (UK Trial
1997).
a. change in growth velocity
The main outcome of the Belgian trial was the effect on long-
term growth and height was measured at three-monthly intervals
during the trial period of one year and then for a further follow-
up year (Belgian Trial 2007). During the first 12 months there
was a significant difference in growth rate of 1.53 cm between
groups, MD -1.53 cm (95% CI -2.37 cm to -0.69 cm). The au-
thors reported that participants did not “catch up” height in the
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12 months following fluticasone discontinuation and a difference
in growth rate of 2.4 cm was reported between the two groups
after 24 months. In a subgroup of these participants growth data
taken two years after treatment discontinuation showed “persis-
tent growth impairment”. Height data was provided to the review
authors for paediatric participants in theCFWISE trial (CF WISE
2006). It was found that there was no significant difference in
height in the participants, 42 fluticasone, 38 placebo, for whom
data was available over the eight months trial duration, MD 0.60
cm (95% CI -0.46 cm to 1.66 cm).
6. Quality of life
In the 1997 UK trial, no significant change in well-being scores
was reported between the two six-week treatment periods (UK
Trial 1997).
7. Adverse effects
Specific adverse effects were reported in two trials (Danish Trial
1997; UK Trial 1997).
In the 1997Danish trial, overall there were 17 adverse events in the
budesonide compared with 13 in the placebo group (Danish Trial
1997). It is unclear whether the numbers reported relate to indi-
viduals or individual episodes, although from the data presented
it would appear that these are episodes. The budesonide group
attended more frequently for outpatient visits than the placebo
group (174 and 146 respectively).Hoarseness of voice andmonilia
(oral thrush) were reported more often in the budesonide group
(six and three occasions and four and two occasions respectively),
as were haemoptysis, pharyngitis and chest pain (two, three, one
respectively in budesonide group compared with no reports in
placebo group). Before and at the end of the trial, 15 partic-
ipants were subjected to an adrenal function test (adrenocorti-
cotropic hormone (ACTH) stimulation test). One participant in
each group had an abnormal response, which was found before
the trial but in both cases the response had normalized by the end
of the trial. It was reported that the response to ACTH did not
differ between groups before or after treatment.
In the 1997UK trial, two potentially drug-related adverse episodes
were reported. One child in the fluticasone group developed peel-
ing of the fingers for three days (in reality it is unlikely this relates
to ICS), and another coughed for five minutes on one occasion
after inhaling fluticasone (given as dry powder) (UK Trial 1997).
The Canadian trial was halted prematurely because it was noted
that six out of the 17 participants enrolled had become colonised
with Pseudomonas aeruginosa for the first time (Canadian Trial
1997). When the code was broken, five of the six participants
enrolled were from the active treatment group (n = 9) and one
from the placebo group (n = 8). In addition one participant from
the active group, previously negative for both Pseudomonas aerug-
inosa and Burkholderia cepacia, grew Burkholderia cepacia for the
first time. Subsequently, the authors identified 56 out of 133 par-
ticipants attending this clinic who were being treated with in-
haled steroids, of whomnine had become culture-positive forPseu-
domonas aeruginosa between three months and three years after
starting this treatment.
In the CF WISE trial (CF WISE 2006) adverse effects were clas-
sified as:
1. CF pulmonary symptoms - 118 fluticasone, 132 placebo;
2. CF non-pulmonary symptoms - 4 fluticasone, 12 placebo;
3. Symptoms not relating to CF - 13 fluticasone 17 placebo.
In the paper it was reported that fewer participants in the fluti-
casone group withdrew from the trial due to lung-related adverse
events (9% compared to 15%) with a relative risk (RR) of 0.59
(95% CI 0.12 to 1.48). There was one drug-related case of oral
candidiasis in a participant taking fluticasone. In addition, there
was no significant increase in rescue bronchodilator use between
the groups (CF WISE 2006).
In the Belgian trial (Belgian Trial 2007) there was no increase in
isolation of Pseudomonas aeruginosa between the two groups of
participants.
8. Survival
There were no deaths in the CFWISE trial (CFWISE 2006); the
remaining trials did not report this outcome.
D I S C U S S I O N
Methodological issues
The effectiveness of long-term treatment with inhaled corticos-
teroids is of clinical relevance in view of its widespread use in clin-
ical practice in Europe and North America. However, the find-
ings of this review suggest that evidence to support this practice
is still lacking. The review identified 13 trials reporting the use
of inhaled steroids in 506 people with CF aged between six years
and 55 years. The methodological quality of the earlier trials was
difficult to assess from published information, specifically with re-
spect to concealment of allocation and the method used to gen-
erate random sequence. Although further information on this has
been provided from some investigators, concealment of allocation
(a key feature of trial validity) remains inadequate or unclear for
most of the earlier trials.
Trials were heterogeneous with respect to inclusion criteria, specif-
ically age, severity of pulmonary involvement, clinical diagnosis of
asthma and chronic lung infection with Pseudomonas aeruginosa.
Trials also differed in duration of treatment. Treatment effects were
assessed for short periods only in the cross-over trials (six weeks)
but for longer periods in the parallel trials. Only one parallel trial
reported treatment given over a two-year period, but follow up
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and reporting at this interval are incomplete. Spirometric indices
of lung function were measured in most trials, but could not be
combined in this review due to incompletely reported or unavail-
able data, as well as to differences in methods used to summarise
data. Although five of the nine investigators contacted following
the first issue of this review have supplied further information, a
pooled estimate of treatment effects for lung function outcomes
has not proved possible. This is either because data are no longer
available or because data related to widely different stages of follow
up.
Inflammatory markers have been reported as outcomes in a sig-
nificant proportion of the trials identified, although these were
not specified as prior outcomes for this review. The relevance of
changes in inflammatory markers to long-term clinical status is
uncertain, but it is likely that the reduction of inflammationwould
be of long-term benefit. In a small uncontrolled study (hence not
eligible for inclusion in this systematic review) in children under
13 years, there was a decrease in neutrophil concentration in bron-
choalveolar lavage after two months of therapy with beclometha-
sone dipropionate, although there was no change in IL-8 concen-
tration (Wojtczak 2001). In contrast, other important outcomes,
such as nutritional status and quality of life, were almost never
reported. Long-term survival was not reported in any trial; but,
given the increasing survival from this condition (especially in
childhood), it is unlikely to be an appropriate outcome measure.
Symptoms were measured in three trials and in one trial a small,
but statistically significant, improvement of uncertain clinical rel-
evance was noted in scores for dyspnoea at rest and cough. The
Epidemiologic Study of Cystic Fibrosis (ESCF) is a multicentre
longitudinal observational study of people with CF in the USA
and Canada which has enrolled over 18,000 participants (Morgan
1999). A follow-up study looked at therapies used in the centres
that reported better lung function results for their clinics (Padman
2007). No differences were found for use of ICS between the 12
centres whose median clinic lung function was in the upper (n =
755 children) versus the 12 centres in the lower quartile (n = 743
children).
Adverse effects
Adverse effects were not consistently assessed, although in most
trials total daily dose of ICS was at the threshold identified in
a systematic review as being associated with adrenal suppression
(Lipworth 1999). Hoarseness of voice and oral candida were re-
ported to be increased in those taking ICS in one trial, but this
observation requires confirmation. An important concern relates
to the risk of acquisition of Pseudomonas aeruginosa infection in
those treated with corticosteroids. Although one trial was halted
prematurely out of this concern, the data available are not conclu-
sive (Canadian Trial 1997). However, a retrospective study of 83
participants under 10 years of age, found no significant effect of
the use of ICS on the risk of early Pseudomonas aeruginosa acquisi-
tion, including those on higher doses (Minicucci 2003). Growth
in childhood is always a concern with long-term corticosteroid
use, and this includes inhaled corticosteroids. The Belgian trial
has shown that one year of high-dose fluticasone adversely affected
growth which did not catch up in the subsequent year (and in a
subgroup followed for two years) (Belgian Trial 2007). However,
the large difference in growth could have been due in part to the
age difference between groups, 9.0 years for the placebo group and
8.2 years for the fluticasone group which might lead to a greater
effect of pubertal growth over 24 months in the older (placebo)
group. This was the first trial to look at growth over a reasonably
long period and has provided important evidence that ICS can
do harm in children with CF. Finally, there have been reports of
children and adults with CF who developed adrenal insufficiency
and sometimes Cushing’s syndrome whilst taking ICS (400 to
1200 mcg/day) together with itraconazole for allergic bronchopul-
monary aspergillosis, due to cytochrome P450 inhibition (Main
2002; Parmar 2002; Skov 2002).
ICS withdrawal
The CFWISE trial is the largest trial of ICS in children and adults
with CF (CF WISE 2006). This trial showed that during the first
six months after stopping ICS therapy, there was no apparent im-
pact (adverse or beneficial), on the onset of acute chest exacerba-
tions, decline in lung function, antibiotic prescribing and rescue
bronchodilator use. Replacing the ICS with placebo was found to
be safe as there was no significant increase in lung-related adverse
effects leading to withdrawal from the trial, nor an increased need
for oral corticosteroids. Many individuals with CF who are on
ICS may no longer need them, but caution is advised due to the
non-significant increase in lung-related adverse effects seen in the
placebo group.
Why no benefit?
The lack of proven benefit of ICS may be due to the failure of
clinical trials to provide the evidence for a benefit that does exist.
The published trials of ICS have a number of flaws, which include
small participant numbers, short treatment periods, inadequate
drug dosages, and in one case lack of a placebo group. The alter-
native view is that benefit has not been proven because there is
no benefit. Delivering inhaled drugs in sufficient quantities to the
airways which are blocked by viscous mucus may be a factor. Poor
inhaler technique, especially in children, can also be a problem.
More relevant may be the nature of the airway inflammation in
CF. It is predominantly neutrophilic and in other airway condi-
tions where neutrophils predominate, for example severe asthma
and acute bronchiolitis, corticosteroids are also not particularly ef-
fective (Green 2002; Patel 2004). Although there is proven benefit
in certain aspects of COPD management (NICE 2004), a biopsy
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study showed that three months of fluticasone did not reduce
the neutrophilic inflammation, despite improvement in symptoms
and exacerbation rate (Hattotuwa 2002). Budesonide and flutica-
sone, and to a lesser extent beclomethasone, have been shown to
prolong neutrophil survival by inhibiting apoptosis, so it might be
that ICS are even promoting inflammation in CF airways (Zhang
2001).
Conclusions
Previous versions of this review have concluded that “evidence
from these trials is insufficient to establish if inhaled corticos-
teroids have a beneficial or harmful effect in people with CF”. The
pendulum of risk/benefit has slowly swung towards risk with the
publication of the Belgian Trial and away from benefit with the
CF WISE 2006 (Belgian Trial 2007; CF WISE 2006). What is
still not proven though is whether ICS can significantly reduce
lung inflammation when given long term. This is important since
if ICS slowed progression of CF lung disease, treatment should
lead to improved morbidity and mortality. However, the down-
stream effects, i.e. lung function and symptoms, have not been
shown to improve with ICS. Given constraints over large RCTs
in CF (relatively small population of potential participants, diffi-
culties with meaningful outcome measures, financial limitations)
and the fact that use of ICS is not high in research priorities, it is
doubtful that such a trial will ever take place. For now, ICS should
be used for symptomatic relief of recurrent wheezing that is not
responsive to bronchodilators alone. Furthermore, the prescribing
practice for an individual with CF should become more like that
for an asthmatic. Justification is needed to start ICS, reassessment
is necessary to see whether they are having an effect (particularly
on any tight cough or wheeze), and consideration is always given
to reducing the dose or stopping the drugs altogether. It is likely
though that the majority of people with CF taking ICS no longer
need to do so. This view has been reflected in the North Amer-
ican consensus document that states “...for patients with CF, 6
years and older, and without asthma or ABPA, the Cystic Fibrosis
Foundation recommends against the routine use of inhaled corti-
costeroids to improve lung function and to reduce exacerbations”
(Flume 2007). A similar view has been expressed at a European
CF Society consensus meeting held in April 2008, the resulting
document of which is in preparation.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review has found little evidence from existing trials to sup-
port the practice of routinely prescribing inhaled steroids in CF.
Specifically, we cannot conclude that inhaled steroids are benefi-
cial but there is some evidence that at a high dose, they adversely
effect growth. There is also some evidence that withdrawal of ICS
in the majority of those already being treated with them is safe.
We recommend that the use of ICS should be restricted to those
with symptomatic wheezing and inwhombenefit has been proven.
Individuals should be regularly reassessed to see whether ICS are
having an effect and consideration should always be given to re-
ducing the dose or stopping the drugs altogether.
Implications for research
The principle unanswered question is whether long-term ICS can
reduce the exuberant lung inflammation so common in people
with CF, and whether they can slow the rate of decline in lung
function and improve survival. Unfortunately it is unlikely that
a randomised controlled trial with sufficient power and length of
follow-up will be conducted, given research priorities in CF and
the difficulties of measuring lung inflammation.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Austrian Trial 1995
Methods Randomised, double-blind, placebo-controlled, parallel trial
Participants 15 CF participants with acute pulmonary exacerbation. Age not given (but was in a
paediatric department)
Interventions All given a 2-week course of intravenous antibiotics. Beclomethasone or placebo started
concurrently and continued for 22 weeks. Beclomethasone 500 mcg 3 times a day
administered by large volume spacer
Outcomes Serum eosinophil cationic protein and myeloperoxidase.
Notes Authors contacted: no reply.
Trial not published in full (3 abstracts) - all available information on methodological
quality, as presented in primary paper, is reported here
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not discussed.
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Described as double-blind, but no details
of who exactly was blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No figures.
Selective reporting (reporting bias) Unclear risk All outcomes reported.
Other bias Unclear risk Trial had never been published in a peer-
reviewed journal.
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Belgian Trial 2007
Methods Randomised, double-blind, case controlled, multicentred trial
Participants 29 pre-pubertal children (20 from1 centre and 9 from another centre) whowere clinically
stable (defined as at least 2 months after any hospital admission and 2 weeks after a
respiratory exacerbation) with FEV1at least 60% predicted. Excluded if had intake of
oral or inhaled steroids for more than 2 weeks within past 6 months or any intake of
these drugs including intranasal steroids within last 4 weeks or a clinical diagnosis of
aspergillosis or participating in another clinical trial
Interventions Fluticasone 500 mcg dry powder inhaler twice daily or lactose placebo dispensed in
identical canister
Outcomes Change in % predicted FEV1 and change in FEV1 20 minutes after inhalation of 400
mcg salbutamol by large plastic spacer device, serum IgG levels, Brasfield chest X-ray
scores, number of respiratory exacerbations, positive P.aeruginosa culture, height.
Notes Of the 20 initially included participants 2 were excluded. 1 participant discontinued
treatment after 3 months and 1 did not keep follow-up appointments
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stated that used random number sequence.
Allocation concealment (selection bias) Unclear risk Not mentioned in text.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Described as double-blind, but nodetails of
who exactlywas blinded. Placebodispensed
in identical canister, so probably partici-
pant and clinician blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Less than 15% of participants were ex-
cluded. Of the 20 initially included par-
ticipants, 2 were excluded (1 discontinued
treatment after 3 months and 1 did not
keep follow-up appointments)
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Low risk Noother potential source of bias identified.
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Canadian Trial 1997
Methods Randomised, double-blind, placebo-controlled, parallel trial
Participants 17 (9 male) clinically diagnosed people with CF aged 6 - 17 years attending the CF clinic
at British Columbia Children’s Hospital, Vancouver. Mean age 7.5 years in fluticasone
group and 9.2 years in placebo group
Interventions Fluticasone 500 mcg given twice daily via a metered dose inhaler and aerosol spacer or
matched placebo. Proposed duration of treatment: 1 year
Outcomes Lung function: FEV1 , FVC, FEF25−75; oxygen saturation; sputumor throat bacteriology;
weight, height and clinical status. All variables measured at baseline and at 3-monthly
intervals throughout the trial. Duration of follow up was 9 months
Notes Trial was halted prematurely because of concerns about possible increased frequency of
pulmonary colonisation with P. aeruginosa among trial participants.
Authors contacted: randomised in blocks of 4 using sealed envelopes; written informed
consent was obtained; age and sex distribution and lung function data by random group
provided. Trial not published in full (1 abstract)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised in blocks of 4, but method of
randomisation not stated
Allocation concealment (selection bias) Low risk Sealed envelopes used.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Described as double-blind, but no details
of who exactly was blinded. Fluticasone or
matched placebo delivered in same way
Incomplete outcome data (attrition bias)
All outcomes
Low risk Trialists provided data to authors as re-
quested.
Selective reporting (reporting bias) High risk Clinical status and nutritional indices were
specified as outcomes in the Canadian trial
but have not been reported to date
Other bias Unclear risk Trial was halted prematurely and trial re-
sults have never been published in a peer-
reviewed journal
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CF WISE 2006
Methods Randomised, double-blind, placebo-controlled withdrawal trial of 8 months duration
Participants 171 (86 male) participants aged over 6 years, diagnosed with CF and attending 18
paediatric and adult UK CF centers. Age range 6 - 53 years. Mean age 14 years in
fluticasone group and 15.8 years in placebo group. Participants excluded if had used oral
corticosteroids within the previous 3 months or very high dose of ICS. Eligibility - age
over 6 years, FEV1 ≥40% predicted.
Interventions Fluticasone propionate given at equivalent dose to ICS participant taking before trial
entry or placebo via a volumatic spacer
Outcomes Primary outcome - time to first respiratory exacerbation.
Secondary outcomes - lung function FEV1, FVC; unplanned courses of intravenous or
oral antibiotics; rescue bronchodilator usage.
Subgroup analysis - age, atopy, steroid dose, baseline FEV1, Pseudomonas status.
Notes 2 month run-in period during which all participants received fluticasone propionate.
Dose unchanged if previously receiving fluticasone, but if previously on budesonide or
beclomethasone, this was changed to fluticasone at a 2:1 ratio
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by permuted blocks of 4.
Local investigators recruited participants in
each centre and then telephoned a dedi-
cated randomisation service at the Royal
Brompton Hospital Clinical Trials and
Evaluation Unit to give participant de-
tails. Randomisationwas performed in per-
muted blocks of 4 to balance the stratify-
ing variables and centres. Participants were
stratified for age (<17 or ³17 years), FEV1
(40 - 60%, 61 - 80% and >80% predicted)
, and atopic status (yes/no). Participants
were randomised in equal proportions to
withdrawal of fluticasone and non-with-
drawal of fluticasone
Allocation concealment (selection bias) Low risk Randomisation was carried out indepen-
dently at the Clinical Trials & Evaluation
Unit of Royal Brompton Hospital and al-
location of individuals was carried out over
the telephone to the trial centres. The study
drug randomisation number was given to
the investigator and faxed to the Pharmacy
department at the Royal Brompton Hos-
pital who then sent out the corresponding
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CF WISE 2006 (Continued)
drug pack to the pharmacy at the local hos-
pital, which provided it to the participant
Blinding (performance bias and detection
bias)
All outcomes
Low risk All trial personnel and participants were
blinded to treatment (placebo)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis was based on all
participants.
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk Noother potential source of bias identified.
Danish Trial 1983
Methods Randomised, double-blind, placebo-controlled, parallel trial
Participants 48 CF participants (29male) including children and adults age 4 - 29 years with a ’typical
history of CF and markedly elevated sweat electrolytes in repeated tests’. Matched in
pairs according to clinical score and, if possible, age and sex. Chronic P. aeruginosa lung
infections for more than 6 months with 2 or more serum pseudomonal precipitins
Interventions Beclomethasone 400 mcg or placebo 4 times a day for 16 weeks via metered dose
inhaler. Treatment started on last day of 2-week course of intravenous carbenicillin and
tobramycin given as hospital inpatient
Outcomes PEFR, FVC, chest X-ray score, erythrocyte sedimentation rate, white blood count, serum
immunoglobulins, serum albumin, serum haptoglobin, serum pseudomonal precipitins
before and after treatment in both groups
Notes Authors contacted: participants matched in pairs by clinical score and randomised within
pairs, but allocation concealment remains unclear; informed verbal consent given; data
provided on age and sex distribution but not lung function. Original data no longer
available
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants matched in pairs by clinical
score and randomisedwithin pairs.Method
of randomisation not stated
Allocation concealment (selection bias) Unclear risk No details available.
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Danish Trial 1983 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Described as double-blind, but no details
of who exactly was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk More than 15% of participants were ex-
cluded, but reasons given and numbers
equal across groups.
5 participants (3 in the beclomethasone
group) withdrawn because of clinical dete-
rioration and started on beclomethasone.
A further 6 either did not attend the con-
trol examination at clinic or discontinued
inhalation therapy. As none from same
matched pair data analysis carried out on
13 pairs (26 participants) only
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk Noother potential source of bias identified.
Danish Trial 1997
Methods Randomised, double-blind, placebo-controlled, parallel trial. Randomised in balanced
blocks of 4 participants. Treatment codes were not broken before clean file was declared
by the data manager according to GCP recommendations
Participants 55 clinically diagnosed CF participants; eligible if: age 8 years (mean age 29 years) and
over; continuous isolation of P. aeruginosa for at least 6 months or significant increase
(not defined) in serum anti-pseudomonas antibodies. Excluded if asthma, allergic bron-
chopulmonary aspergillosis; colonisation with Burkholderia cepacia, pregnant, severely
impaired cardiac, hepatic or renal function (not defined); treated with inhaled or oral
steroids in previous 2 months
Interventions Budesonide 800 mcg twice daily as a dry powder or lactose powder inhaled through a
spacer device given as 2 consecutive treatment periods each of 3 months duration with
2-week elective course of intravenous antibiotics given at start and between 2 treatment
periods
Outcomes FEV1, FVC, bronchial reactivity assessed by histamine PC20 and exercise test; Sputum
inflammatory markers: tumour necrosis factor, interleukin-1 receptor antagonist, poly-
morphonuclear granulocyte elastase, free elastolytic activity; plasma inflammatory mark-
ers: polymorphonuclear granulocyte elastase, precipitating antibodies against P. aerug-
inosa; adrenal function (ACTH stimulation test) in those under 18 years; compliance
assessed by counting number of doses left in Turbuhalers at each clinic visit; adverse ef-
fects: hoarse voice, oral thrush, haemoptysis, cough, pneumothorax, chest pain, abscess,
pharyngitis, pneumonia, infection or fever
Notes
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Danish Trial 1997 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised in balanced blocks of 4 par-
ticipants. Method of randomisation not
stated
Allocation concealment (selection bias) Low risk Stated that treatment codes were not bro-
ken before clean file was declared by the
data manager according to GCP recom-
mendations
Blinding (performance bias and detection
bias)
All outcomes
Low risk Described as double-blind, but no details
of who exactly was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysed on both an ’intention-to-treat’
and ’completed treatment’ basis. Partici-
pants considered not to have completed
treatment if period between intravenous
courses was < 8 weeks or > 20 weeks or if
sum of 2 treatment periods < 18 weeks or
> 40 weeks
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Low risk Noother potential source of bias identified.
Dutch Trial 1995
Methods Double-blind, placebo-controlled, cross-over trial.
Participants 16 volunteers (mean age 27 years; range 16 - 45 years) with CF diagnosed by sweat test.
All with baseline FEV1 > 25% predicted, no acute pulmonary exacerbation in previous
6 weeks, PC20 FEV1 histamine < 16 mg/ml. Excluded pregnant, currently taking oral
steroids, severe concomitant disease; participants stopped sodium cromoglycate, antihis-
tamines and theophylline preparations before trial
Interventions Budesonide or placebo given for 6 weeks by blinded metered dose inhalers supplied by
pharmaceutical company. Budesonide dose 200 mcg per puff, given as 4 puffs (800 mcg)
twice daily. Run in period of 2 weeks, no washout period
Outcomes Lung function tests: FEV1, FVC, bronchial reactivity as assessed by histamine provoca-
tion, twice daily peak expiratory flow rates. Hospital admissions for respiratory exacer-
bations; antibiotic use; symptom diary
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Dutch Trial 1995 (Continued)
Notes Written to first author but left department with no forwarding details. All available
information on methodological quality, as presented in primary paper, is reported here
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not discussed.
Allocation concealment (selection bias) Low risk Budesonide or placebo given by blinded
metered dose inhalers supplied by pharma-
ceutical company
Blinding (performance bias and detection
bias)
All outcomes
Low risk Described as double-blind, but no details
of who exactly was blinded. Budesonide or
placebo given for 6 weeks by blinded me-
tered dose inhalers
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear.
Selective reporting (reporting bias) High risk Hospital admissions and antibiotic usage
were specified as outcomes, but no data
were reported
Other bias Unclear risk No wash-out period described.
German Trial 1999
Methods Randomised, open-labelled, prospective, parallel trial.
Participants 26 adults (13 males) with ’stable’ CF (median age 26 years; range 16 years to 38 years).
None on oral steroids and no ICS within 6 weeks
Interventions Fluticasone propionate 500 mg bid as dry powder inhaler or control group (non-steroid
medication) given for 6 weeks
Outcomes Lung function tests: FEV1, FVC,MEF25−75; sputum: leukocyte count, myeloperoxidase
activity, baseline and stimulated superoxide anion release; self-reported symptoms elicited
by questionnaire
Notes Author contacted with request for information regarding allocation concealment and
numbers of participants included in analysis of FEV1 outcome.
Risk of bias Risk of bias
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German Trial 1999 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Prior to the trial, a randomnumber rowwas
generated, and participants with even and
odd numbers were consecutively divided
into the treatment and control groups. Low
risk of bias because first participant allo-
cated from random number row
Allocation concealment (selection bias) High risk Alternation used - risk of bias as investiga-
tors could foresee which group next partic-
ipant would be allocated to
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not mentioned.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Low risk Noother potential source of bias identified.
Irish Trial 1995
Methods Randomised, double-blind, placebo-controlled, cross-over trial
Participants 7 adults (4 male) with mild CF: mean (SE) % predicted FEV1: 85.4 (6.4) %; mean (SE)
% predicted FVC: 95.7 (6.4)%. All grew P. aeruginosa in sputum; 2 participants atopic
(not defined).
Interventions Beclomethasone 1500 mcg daily or matched placebo for 4 weeks with 4-week washout
period
Outcomes Spirometry and bronchial reactivity measured by methacholine challenge. Markers of
inflammation in blood and sputum: alpha one protease inhibitor, neutrophil elastase
and interleukin 8
Notes Authors contacted: randomisation by ’envelope’; no full publication; no additional data
provided
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation by ’envelope’.
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Irish Trial 1995 (Continued)
Allocation concealment (selection bias) Low risk Sealed envelopes used.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Described as double-blind, but no details
of who exactly was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis was based on all
participants.
Selective reporting (reporting bias) Low risk All outcomes reported in the abstract.
Other bias Unclear risk Trial has never been published in a peer-
reviewed journal.
Swiss Trial 1996
Methods Randomised, parallel trial.
Participants 50 adults and children (mean age 19.8 years) with CF;minimum age 6 years; hospitalised
for at least 30 days in a rehabilitation centre in Switzerland; no systemic or inhaled
steroids in last 3 months; moderate to severe bronchial obstruction as evidenced by
FEV1 < 55% predicted at time of entry. Participants who used systemically administered
corticosteroids during the trial period were excluded post-randomisation. 49 completed
trial, 25 in intervention group
Interventions Beclomethasone 1500 mcg per day by metered dose inhaler through a spacer device
administered either twice or three times a day for 30 days. Control group not given
placebo inhalation and hence no blinding
Outcomes Lung function tests: FEV1, FVC; plethysmographic assessment of airway resistance and
thoracic gas volume; single breath carbon monoxide diffusion test
Notes Authors contacted: no reply.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no details given.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
All outcomes
High risk Lack of a placebo in the control arm.
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Swiss Trial 1996 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Participants who used systemically administered corticos-
teroids during the trial periodwere excludedpost-randomi-
sation
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Low risk No other potential source of bias identified.
Turkish Trial 2008
Methods Randomised, but inadequate information given.
Participants 29 individuals with CF with mean age 10.5 years (69% female). Excluded if taken any
form of steroids in last 2 months
Interventions Treatment group (n = 17) received 2 mg/day nebulised budesonide.
Control group (n = 12) received nebulised ’serum physiologic’ [Is this 0.9% normal
saline?].
No information given re length of treatment.
Outcomes BHR bymethacholine challenge.Oxidative damage - plasmaMDA levels. Inflammation
- hsCRP and oxidative burst of monocytes, sputum neutrophils, WBC
Notes No results with statistical analysis given. They state that plasmaMDA,WBC and sputum
neutrophil%decreased significantlywith budesonide; but nodifferences inBHR, clinical
or inflammatory parameters
Although this trial is included in the review, insufficient information is given so that it is
not included in any analyses. The trial is available as an abstract only and is unpublished
in full
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Abstract only, described as randomised but
methods not discussed
Allocation concealment (selection bias) Unclear risk Abstract only, not discussed.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not discussed.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No data given in abstract.
Selective reporting (reporting bias) Unclear risk Abstract only, insufficient information to
make judgement.
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Turkish Trial 2008 (Continued)
Other bias Unclear risk Trial has never been published in a peer-
reviewed journal.
UK Trial 1996
Methods Randomised, double-blind, placebo-controlled, parallel trial
Participants 36 participants, aged 16 years to 41 years, with established CF pulmonary disease
Interventions Fluticasone propionate 500 mcg twice daily via a metered dose inhaler and spacer or
matching placebo given for 2 years
Outcomes Home diary card of symptoms; domiciliary lung function tests using spirometer to
measure FEV1, FVC, PEFR.
Notes At 24 months data on FEV1 were only available on 8 participants in the fluticasone
group and 9 in the placebo group.
Authors contacted: no full publication and no further data available
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no further
details given.
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Described as double-blind. Fluticasone or
matching placebo.
Incomplete outcome data (attrition bias)
All outcomes
Low risk More than 15% of participants were ex-
cluded, but reasons given and numbers
equal across groups
At 24 months data on FEV1 were only
available on 8 participants in the fluticas-
one group and 9 in the placebo group
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Unclear risk Trial has never been published in peer-re-
viewed journals.
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UK Trial 1997
Methods Double-blind, placebo-controlled, randomised, sequence cross-over trial
Participants 23 children (11 boys), mean age 10.3 years (range 7 years to 17 years) with clinically
diagnosed CF; 65% homozygous and 30% heterozygous for delta F508.
Eligible if aged 6 - 17 years, able to perform spirometry reliably, use a Diskhaler and
produce sputum. Ineligible if: oral or inhaled corticosteroid use in previous 6 months,
clinical diagnosis of asthma, use of sodium cromoglycate or beta-2 agonists in previous
6 months, lower respiratory infection requiring antibiotics in previous 3 weeks, CF-re-
lated diabetes, portal hypertension, allergic bronchopulmonary aspergillosis, Burkholde-
ria cepacia in sputum.
Interventions Fluticasone propionate by dry powder inhaler in 2 doses equivalent to 400 mcg per day
or matched placebo given for 6-week period with 4-week washout period
Outcomes Primary outcome measure: change from baseline in sputum inflammatory markers inter-
leukin-8, tumour necrosis factor-alpha, free neutrophil elastase and neutrophil elastase
bound to alpha 1 antiprotease. Covariates: atopic status, disease severity as assessed by
FEV1.
Secondary outcomes: FEV1, FVC, oxygen saturation, weekly retrospective symptom
score, weekly score for well-being and appetite, compliance as assessed by unused disks
Notes 1 participant failed to comply with treatment so the efficacy sample used for analysis
consisted of 22 participants.
Authors contacted: randomised by sealed envelopes prepared by pharmaceutical com-
pany; lung function data provided
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but details of
process not discussed
Allocation concealment (selection bias) Low risk Randomised by sealed envelopes prepared
by pharmaceutical company
Blinding (performance bias and detection
bias)
All outcomes
Low risk Described as double-blind, but nodetails of
who exactly was blinded. Fluticasone pro-
pionate or matched placebo
Incomplete outcome data (attrition bias)
All outcomes
Low risk Less than 15% of participants were ex-
cluded.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Unclear risk No other potential source of bias identified.
ACTH: adrenocorticotropic hormone
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BHR: bronchial hyperreactivity
CF: cystic fibrosis
FEF25−75: forced expiratory flow rate
FEV1: forced expiratory volume at 1 second
FVC: forced vital capacity
GCP: good clinical practice
hsCRP: high sensitivity C-reactive protein
mcg: microgram
MDA: malondialdehyde
P. aeruginosa: Pseudomonas aeruginosa
PEFR: peak expiratory flow rate
SD: standard deviation
SE: standard error
WBC: white cell count
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Australia Trial 2000 Unable to determine whether treatments were allocated by random or quasi-random methods
Bessaci 2008 Trial of seretide (which contains an inhaled steroid) plus salmeterol which is not a steroid. Since this trial does
not consider an ICS alone, it can not be included
USA Trial 1996 Not a clinical trial - prospective observational study.
USA Trial 1998 Randomised double-blind trial but in this abstract the outcomes reported were not relevant to those specified
in this review
ICS: inhaled corticosteroid
Characteristics of studies awaiting assessment [ordered by study ID]
Kapustina 2008
Methods Not clear if study was randomised and if so how.
Participants 40 children with CF (23 females and 17 males) aged 5 to 17.4 years. All patients have “severe” phenotype
Interventions Group 1 (14 children): inhaled corticosteroids for mean (SD) 34.29 (37.62) months (minimum 6months; maximum
120 months).
Group 2 (26 children): oral steroids (0.5 mg/kg every other day) for mean (SD) 33.04 (37.98) months (minimum
1 month; maximum 185 months)
All patients received adequate basic therapy including calcium (500-1000 mg/day) and vitamin D (200-400 IU/day)
supplementation
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Kapustina 2008 (Continued)
Outcomes BMD (g/cm2) in the lumbar spine
Notes Contacted authors for clarification on methods.
BMD: bone mineral density
CF: cystic fibrosis
IU: international units
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D A T A A N D A N A L Y S E S
Comparison 1. Inhaled corticosteroid versus placebo




participants Statistical method Effect size
1 Mean absolute FEV1 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 24 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Per cent predicted FEV1 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 At 30 days 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 At 6 months pre
salbutamol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 At 6 months post
salbutamol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 At 12 months pre
salbutamol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 At 12 months post
salbutamol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Per cent predicted FEV1
(withdrawal study)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Change in per cent predicted
FVC
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 At 30 days 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Change in per cent predicted
FVC (withdrawal study)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Average patient days in hospital 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 At 9 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Average patient days on
antibiotics
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 At 9 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Growth velocity 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9 Growth velocity (withdrawal
study)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 After 8 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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WH A T ’ S N E W
Last assessed as up-to-date: 15 August 2016.
Date Event Description
22 August 2016 New citation required but conclusions have not changed Since no new data have been added to the review, our
conclusions remain the same
22 August 2016 New search has been performed A search of the Cochrane Cystic Fibrosis and Genetic
Disorders Review Group’s Cystic Fibrosis Trials Register
did not identify any new references potentially eligible
for inclusion in the review
H I S T O R Y
Protocol first published: Issue 1, 1998
Review first published: Issue 1, 2000
Date Event Description
6 October 2014 New citation required but conclusions have not
changed
Since we have not been able to include any new in-
formation at this update, our conclusions remain the
same
6 October 2014 New search has been performed A search of the Cystic Fibrosis & Genetic Disorders
Review Group’s Cystic Fibrosis Trials Register did not
identify any new references which were potentially el-
igible for inclusion in the review. We have updated the
plain language summary in light of new guidance
24 September 2012 New search has been performed A search of the Cystic Fibrosis & Genetic Disorders
Trials Register did not identify any new references for
this review
24 September 2012 New citation required but conclusions have not
changed
No new data were added; hence the conclusions of this
review have not changed
6 October 2010 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
identified four new references to three trials. One of
thesewas an additional reference to an already included
trial (Turkish Trial 2008). One trial (two references)
was excluded (Bessaci 2008) and one trial is listed as
’Characteristics of studies awaiting classification’ until
the authors can clarify the methods used in their study
(Kapustina 2008).
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(Continued)
26 April 2010 Amended Contact details updated.
5 November 2008 New citation required and conclusions have changed The background and discussion sections have been re-
drafted; the conclusions and recommendations have
been changed
Sarah Walters has stepped down as co-author at this
update.
5 November 2008 New search has been performed The latest searches identified three new references to
three studies. One of these references was to a study
previously listed as Studies awaiting classification and
this study has now been included in the review (CF
WISE 2006). The other two new studies have both
been included (Belgian Trial 2007; Turkish Trial 2008)
; A further study, previously listed as Studies awaiting
classification has now been excluded (Australia Trial
2000).
19 June 2008 Amended Converted to new review format.
24 April 2006 New search has been performed A search of the Group’s Trials Register did not identify
any new references for this review. There has been a
publication of the CFWISE trial (previously Balfour-
Lynn 2001, personal communication - now Balfour-
Lynn 2005)
16 May 2005 New search has been performed The search of the Group’s Cystic Fibrosis Trials Reg-
ister identified one reference, which was subsequently
found not to be eligible for inclusion within the review
19 February 2004 Amended The lead reviewer is now Dr Ian Balfour-Lynn; Prof
Carol Dezateux remains as a co-reviewer
19 February 2004 New search has been performed One further trial has been identified for this updated
review (German Trial 1999). This has not altered the
conclusions of the earlier review. This update also in-
cludes some further information provided from au-
thors of five earlier trials (Canadian Trial 1997;Danish
Trial 1983; Irish Trial 1995; UK Trial 1996, UK Trial
1997). This has allowed methodological quality to be
more clearly defined in four trials and has provided
data on primary and secondary outcomes as well as
study population in three.Data have been entered into
the review and are in summarised inData andAnalyses
(comparison 01, outcomes 05, 06, 07 and 08). Meta-
analysis has not been possible reflecting heterogeneity
in study design and unavailability of relevant data
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In a post hoc change we added ’adrenal insufficiency’ to the list of adverse events we planned to investigate.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Inhalation; Anti-Inflammatory Agents [∗administration & dosage; adverse effects]; Budesonide [administration &
dosage; adverse effects]; Cystic Fibrosis [∗drug therapy]; Fluticasone [administration & dosage; adverse effects]; Glucocorticoids [ad-
ministration & dosage; adverse effects]; Randomized Controlled Trials as Topic
MeSH check words
Adolescent; Adult; Child; Humans; Middle Aged; Young Adult
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